Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Hoai-Thu Thai"'
Autor:
Marc Cerou, Hoai‐Thu Thai, Laure Deyme, Sophie Fliscounakis‐Huynh, Emmanuelle Comets, Patrick Cohen, Sylvaine Cartot‐Cotton, Christine Veyrat‐Follet
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 6, Pp 941-953 (2024)
Abstract A joint modeling framework was developed using data from 75 patients of early amcenestrant phase I–II AMEERA‐1‐2 dose escalation and expansion cohorts. A semi‐mechanistic tumor growth inhibition (TGI) model was developed. It accounts
Externí odkaz:
https://doaj.org/article/7edf3331df7a41158673908d8fb6a32c
Autor:
Hoai‐Thu Thai, Kimiko Koiwai, Yoshihisa Shitara, Hirotaka Kazama, Jean‐Baptiste Fau, Dorothée Semiond, Christine Veyrat‐Follet
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 12, Pp 1846-1858 (2023)
Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of s
Externí odkaz:
https://doaj.org/article/daa28da7c7994013bf748c2247ab7421
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 6, Pp 766-777 (2022)
Abstract Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clini
Externí odkaz:
https://doaj.org/article/72a8ca4364ed43ceb08268319c1c852e
Autor:
Kimiko Koiwai, Raouf El‐Cheikh, Hoai‐Thu Thai, Claire Brillac, Jean‐Baptiste Fau, Christine Veyrat‐Follet, Marie‐Laure Risse, Helgi van deVelde, Dorothée Semiond, Laurent Nguyen
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)
Abstract This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with rela
Externí odkaz:
https://doaj.org/article/af2cc48054174339a0403cbbf840ec73
Autor:
Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel‐Dedieu, Bernard Sebastien, Hoai‐Thu Thai, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Helgi van de Velde, Christine Veyrat‐Follet, Dorothée Semiond
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 11:766-777
Isatuximab is an approved anti-CD38 monoclonal antibody with multiple antitumor modes of action. An exposure-response (E-R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who r
Autor:
Nadia Gaudel, Dorothée Semiond, Hoai-Thu Thai, Helgi van de Velde, Jean-Baptiste Fau, Geraldine Ayral, Christine Veyrat-Follet, Marc Cerou, Bernard Sebastien
Publikováno v:
British Journal of Clinical Pharmacology. 88:2052-2064
Aims Addition of isatuximab to pomalidomide/dexamethasone (Pd) significantly improved progression-free survival (PFS) in patients with relapsed/refractory multiple myeloma (RRMM). We aimed to characterize the relationship between serum M-protein kine
Autor:
Marie-Laure Risse, Raouf El-Cheikh, Christine Veyrat-Follet, Laurent Nguyen, Jean-Baptiste Fau, Kimiko Koiwai, Hoai-Thu Thai, Claire Brillac, Dorothée Semiond, Helgi van de Velde
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 8, Pp 928-940 (2021)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
This analysis describes the pharmacokinetic/pharmacodynamic (PK/PD) modeling framework that supported selection of the isatuximab (anti‐CD38 monoclonal antibody) dosing regimen alongside its early clinical development in patients with relapsed/refr
Autor:
Emma, Gerard, Sarah, Zohar, Hoai-Thu, Thai, Christelle, Lorenzato, Marie-Karelle, Riviere, Moreno, Ursino
Publikováno v:
Biometrics. 78(1)
Phase I dose-finding trials in oncology seek to find the maximum tolerated dose of a drug under a specific schedule. Evaluating drug schedules aims at improving treatment safety while maintaining efficacy. However, while we can reasonably assume that
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Dorothée Semiond, Hoai-Thu Thai, Bernard Sebastien, Helgi van de Velde, Nadia Gaudel-Dedieu, Marc Cerou, Christine Veyrat-Follet
Publikováno v:
Cancer Research. 81:1372-1372
Introduction: Isa is a CD38 monoclonal antibody with multiple modes of action for killing tumor cells. Isa, in combination with pomalidomide and dexamethasone (Pd), is approved for the treatment of adult pts with RRMM who have received ≥2 prior the